fda tirzepatide ban Compounded GLP-1 ban: What providers need to know FDA says 'no clinical need'

In January 2025, Metsera, a New York-based obesity healthcare company, announced positive topline results from its Phase IIa clinical trial for MET-097i, a glucagon-like peptide-1 receptor agonist (GLP-1RA)

How to inject: Inject once a week, on any day, with or without food

Appointments Getting an appointment with Cleveland Clinics triple-negative breast cancer experts is easy

The institute recommended that existing GLP-1 makers, and those with products in the pipeline, should consider steep discounts to prices in exchange for higher volume. What has to happen is we have to move from a low-volume, high-price business model, to a high-volume, low-price business model, Nunn said